{
    "nctId": "NCT00395655",
    "briefTitle": "Hydralazine and Valproate Added to Chemotherapy for Breast Cancer",
    "officialTitle": "A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma",
    "overallStatus": "TERMINATED",
    "conditions": "Locally Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "Global DNA methylation",
    "eligibilityCriteria": "Inclusion Criteria:\n\nAged 18 and older; histologically proven invasive T2-3, N0-2, and M0 (stages IIB-IIIA) breast carcinoma; Eastern Cooperative Oncology Group performance status \u22642. Hematological function: Absolute leukocyte count \u22654,000/mm3, platelets \u2265100,000/mm3, hemoglobin \u22659.0 g/dL. Hepatic function: total bilirubin, aspartate amino transferase and alanine amino transferase \\<1.5 the upper normal limit. Renal function: creatinine \u22641.2 mg/dL or a calculated creatinine clearance of \u226560 mL/min. Written informed consent.\n\nExclusion Criteria:\n\nA history of allergy to sulphas, hydralazine, or magnesium valproate. Past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician. Previous use of the experimental drugs. Pregnancy and breast-feeding. Uncontrolled systemic disease or infection.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}